View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Your vote is Important!
Please vote your proxy online now or by phone by
You must register to be eligible to participate in the meeting.
Date: March 2, 2023
Time: 5:00 PM ET
Register By: March 1, 2023 at 5:00 PM ET
Enanta is a clinical stage biotechnology company dedicated to creating oral drugs for viral infections and liver diseases. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus (MAVYRET® and VIEKIRA PAK®, respectively). Currently, we have a diverse and robust pipeline, including one of the most advanced respiratory virology treatment portfolios in the industry, which we are progressing through clinical development with programs for respiratory syncytial virus, SARS-CoV-2 and human metapneumovirus. We are also advancing a clinical stage program for a combination treatment for chronic hepatitis B virus infection.